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ABSTRACT & KEY WORD PAGE 
 
Factors predicting poor glycaemic control in the first two years of childhood onset type 1 
diabetes in a cohort from East London, UK: Analyses using mixed effects fractional 
polynomial models   
 
Background/aims: Poor early glycaemic control in childhood onset type 1 diabetes (T1D) is 
associated with future risk of acute and chronic complications. Our aim was to identify the predictors 
of higher glycated hemoglobin (HbA1c) within 24 months of T1D diagnosis in children and 
adolescents.  
 
Methods: Mixed effects models with fractional polynomials were used to analyse longitudinal data 
of patients <19 years of age, followed from T1D diagnosis for up to 2 years, at three diabetes clinics 
in East London, UK.   
 
Results: A total of 2209 HbA1c observations were available for 356 patients (52.5% female; 64.4% 
non-white), followed from within 3 months of diagnosis during years 2005 to 2015, with a mean±SD 
of 6.2±2.5 HbA1c observations/participant. The mean age and HbA1c at diagnosis were 8.9±4.3 
years and 10.7% ±4.3% (or expressed as mmol/mol HbA1c mean±SD 92.9±23.10 mmol/mol) 
respectively.  
 
Over the 2 years following T1D diagnosis, HbA1c levels were mostly above the National Institute for 
Health, Care and Excellence (NICE), UK recommendations of 7.5% (<58mmol/mol). Significant 
(p<0.05) predictors of poorer glycaemic control were: Age at diagnosis (12-18 years), higher HbA1c 
at baseline (>9.5% i.e. >80mmol/mol), clinic site, non-white ethnicity and period (pre-year 2011) of 
diagnosis. Additionally in univariable analyses, frequency of clinic visits, HbA1c at diagnosis and 
type of insulin treatment regimen showed association with poor glycaemic control (p<0.05). 
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Conclusions: Major risk factors of poorer glycaemic control during 3-24 months following childhood 
onset T1D are: diagnosis prior to 2011, higher HbA1c levels at baseline, age at diagnosis, non-white 
ethnicity and clinic site.  
 
Key words: Predictors, HbA1c, Type 1 diabetes mellitus, paediatric, longitudinal analyses  
 
LIST OF ABBREVIATIONS 
AIC: Akaike information criterion 
BIC: Bayesian information criterion 
BMI: Body mass index 
DKA: Diabetic Ketoacidosis 
HbA1c: Glycated haemoglobin A1c 
IMD: Indices of multiple deprivations  
NICE: National Institute for Health, Care and Excellence 
T1D: Type 1 diabetes 
-2LL: - 2 Log likelihood 
 
INTRODUCTION 
Evidence suggests that early glycaemic control in childhood onset Type 1 Diabetes (T1D) tracks 
into later life (1-4) and predicts risk of future vascular complications (5, 6). Studies in adults show a 
reduced risk of vascular complications and mortality in those who maintained lower HbA1c levels 
during early stages of the disease (7, 8). It is therefore important to identify if this is the case or 
whether other factors influence glycaemic trends from T1D diagnosis in children and adolescents (9, 
10). 
 
Poor glycaemic control is seen in children and adolescents soon after T1D diagnosis (11). But 
factors influencing these outcomes are poorly understood due to studies: with small sample size, 
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focused on older children and adolescents or investigated a limited number of demographic 
variables (12). This causes a difficulty in identifying and predicting a “risk signature” of poor control 
during the course of the disease in young T1D patients (13).  
 
In order to investigate the predictors (socio-demographic, biological and clinical) affecting the 
glycaemic control within 24 months of T1D diagnosis in children and adolescents, we undertook a 
retrospective analysis of data collected prospectively from three diabetes clinics based in East 
London, UK. 
 
METHODS 
We investigated the predictors of glycaemic control (HbA1c levels) during 3 to 24 months from T1D 
diagnosis in young children and adolescents. Data included paediatric (<19 years of age at 
diagnosis) patients, recorded in the hospital database as newly diagnosed with T1D, in the period 
between 1 January 2005 and 31 December 2015 and receiving care from one of the three paediatric 
diabetes clinics of the Barts Health NHS Trust in East London, UK.  
Due to increasing knowledge of more rare causes of diabetes, patients may have been misidentified 
during the study period as Type 1 Diabetes (default in the database), and may have had Type 2 
Diabetes, Maturity Onset Diabetes or secondary diabetes. The records of three patients with very 
low HbA1c were looked at and these patients most likely did not have T1D and were excluded. 
Each of the three clinics had a separate but unequal, multi-disciplinary diabetes specialist care team 
made up of clinicians, nurses, dieticians, psychologists and with access to interpreters. For example, 
a 24 hour paediatric Diabetes consultant on call service was available at only one of the clinics. The 
three clinics became part of a network in 2012 but care continued to be delivered by the respective 
care team at each clinic as per the updated care package recommended by the National Institute of 
Health and Care Excellence (NICE) (14). Type and methods for the electronic recording of 
anthropometric, socio-demographic and clinical data, collected at diagnosis and at each clinic visit 
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were not always uniform between the three clinics. For example, one of the three clinics recorded 
data of fewer patients in the first 3 months from T1D diagnosis (Supplementary figure panel 1a&b).  
 
Variables 
We used HbA1c, a measure of average blood glucose over the previous 8-12 weeks, as our marker 
of diabetes control and as the dependent variable in these analyses. Venous and finger HbA1c 
measured using BioRad Variant II Turbo (in laboratory) and Siemens/Bayer DCA 2000 (in clinic) 
respectively at diagnosis and each clinic visit. The HbA1c values recorded as percentages were 
converted to mmol/mol using the formula: (HbA1c value in %−2.15) × 10.929. Baseline was defined 
as period within 3 months of T1D diagnosis and patients with baseline measurements were eligible. 
HbA1c levels at diagnosis (measurement within the first month of diagnosis) and at baseline 
(averaged HbA1c measurements within first 3 months of diagnosis) were assessed by tertiles or 
categorized into low (<7.5% or <58mmol/mol), moderate (7.5- 9.5% or 58-80 mmol/mol) and high 
(> 9.5% or >80mmol/mol) based on UK targets that were acceptable during the study period.  
 
Based on our systematic review (12) and captured in the dataset, potential predictors of HbA1c 
which we used as independent variables in our analyses were sex, age at diagnosis, 
season/month/year/period of T1D diagnosis, ethnicity, index of multiple deprivation (IMD), clinic site, 
number of clinic visits, insulin regimen, body mass index (BMI), pH at diagnosis, HbA1c at diagnosis 
and baseline. 
 
We tested the accuracy of the data in a number of patients and found that the insulin treatment may 
have been inaccurately documented in the database. Sometimes details of insulin regimen such as 
dosage, injection frequency and pump treatment were missing during the earlier years (prior to 2012) 
and before the individual clinics joined to form a network.  
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Age at diagnosis was treated as a categorical variable and stratified into the following groups: 0–5 
(preschool), 6–11 (pre-pubertal), and 12-18 (pubertal/adolescent) years. Season of diagnosis was 
categorized into autumn (September to November), winter (December to February), spring (March 
to May) and summer (June to August). Period of diagnosis was categorized into pre-2011 and post-
2011 to check for differences in outcomes between the two periods since the three diabetes clinics 
became part of the same network in 2012. Ethnicity was categorized into white and non-white for 
the main analysis. Socioeconomic status was measured using the UK IMD (2010), which gives a 
relative measure of neighborhood-level socioeconomic deprivation based on seven domains for 
small areas in England: income, employment, health and disability, education, skills and training, 
barriers to housing and services, living environment and crime. IMD scores were categorized into 
three groups with 3 being least deprived and 1 being most deprived (15). The number of clinic visits 
per patient was treated as a continuous variable.  
 
Insulin treatment (between years 2005-2015) was categorized as continuous subcutaneous insulin 
infusion pump, 3 or more injections per day or 1 or 2 injections per day. BMI (obtained from the 
records of physical examination involving measurements of height and weight) measured as kg/m2 
at each clinic visit, was treated as a continuous variable and was standardized to BMI (WHO) z-
scores. These were further categorized into normal weight, overweight/obese and thin (16).  
 
 Whole blood pH at diagnosis was treated as a continuous variable and in a sensitivity analysis was 
categorized into acidotic (pH<7.3), normal (pH 7.3 to 7.45) and alkalotic (pH>7.45).  
  
Analyses 
Baseline characteristics of the cohort were reported as means and standard deviations for 
continuous variables or counts and percentages for categorical variables. Baseline characteristics 
were compared across HbA1c categories at baseline using a global χ² test for categorical variables 
or a Wald test from linear regression for continuous variables. 
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Repeated measurements of the outcome HbA1c were modelled using mixed effects models. 
Fractional polynomials were used to account for nonlinear trajectories of HbA1c over time (17, 18). 
We estimated models for both 0 to 24 months (Model 1: with 253 T1D patients followed from 
diagnosis) and 3 to 24 months (Model 2: with 335 T1D patients followed from baseline), as data 
showed dramatic instability in HbA1c during the first three months after diagnosis, as expected. In 
this paper we report the results of the investigations of predictors of HbA1c levels from 3 to 24 
months in the 335 patients who were followed from baseline. The trajectories and predictors of 
HbA1c during 0-3 months will be studied in depth and reported separately. The polynomial terms in 
the model were chosen by comparing model fit amongst all fractional polynomial models with one, 
two or three polynomial terms with any combination of the following polynomial powers of time: (-2 
-1 -0.5 0 0.5 1 2 3), where 0 represents log(t) and a repeated power (p p) indicates the functions !" 
and log	(!)!". The outcome model for 0 to 24 months (Model 1) was  
)*+1-.	(t) = 12 + 14log	(!) + 15! + 16!5 + *2,. + *4,.log	(!) + *5,.! + *6,.!5 + 8. 
and the outcome model for 3 to 24 months (Model 2) was 
)*+1-.(t) = 12 + 14√! + 15log	(!)√! + *2,. + *4,.√! + *5,.log	(!)√! + 8. 
where )*+1-.	(!)  is the outcome of interest for individual : . 12 ,14 , 15  and 16  are fixed effect 
coefficients describing the population average trajectory of the outcome and *2,., *4,., *5,.  and *6,. 
are normally distributed random effects describing the deviation of individual :’s trajectory from the 
population average. The best model was selected within each class of one-term, two-term or three-
term models. Fixed effects and random effects were included in the model selection procedure. 
However, the expectation of the random effects was assumed to be zero. Additionally, both the 
Akaike information criterion (AIC) and the Bayesian information criterion (BIC) were used to assess 
model fit (Supplementary tables S1 a & b give the AIC and BIC results from each class of models). 
Time-dependent predictors were not included in the model. However, mean of HbA1c and BMI 
measurements taken during the 0-3 month period from diagnosis were used as predictors during 3-
24 month follow-up. 
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To study the predictors of glycaemic control between 3 and 24 months of diagnosis, predictor 
variables were included in the mixed effects model. The effect of the predictor variables represents 
a shift in the population average trajectory and can therefore be interpreted as a mean difference in 
HbA1c levels over time. Initially each predictor variable was separately added to the models 1 and 
2, and significant predictor variables were then included in a multivariable model. Predictors showing 
significant interactions with sex, clinic site and age at diagnosis were also included in the 
multivariable model. All models include √ and log*√ functions of time as both fixed and random 
effects. Results for potential predictors were reported as mean differences and 95% confidence 
intervals (CI). Sensitivity analyses were conducted where appropriate.  
 
Additionally, the above initial mixed model with each predictor variable were then fitted to include 
interactions between the predictor variable and the polynomial time functions, allowing the shape of 
the HbA1c trajectory to depend on the level of the predictor variable.   
 
Analyses were performed using Stata 15, StataCorp. College Station, TX, 2015. The fractional 
polynomial models were fitted using the stata “fp” command. 
 
RESULTS 
A total of 356 T1D patients (52.5% female) with 2209 HbA1c observations (mean 6.2±2.5 HbA1c 
observations/participant) and a follow-up of 2 years from T1D diagnosis at the 3 sites, during the 
study period (2005-2015) were eligible for inclusion in our study at baseline.  
However, in the analyses of data covering the 3-24 months period from diagnosis, a total of 335 
patients (53.4% female) with 1627 HbA1c observations (mean 7.4±2.0 HbA1c 
observations/participant) were eligible. Of these, 253 (75.5%) patients were followed from and had 
HbA1c measurements within first month of T1D diagnosis (See Table 1 for baseline characteristics). 
Insulin regimen may have been inaccurately documented for some patients and data on insulin 
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dosage was missing, which restricted the analysis of this variable against our objectives. pH at 
diagnosis (mean ±SD 7.27±0.16) was available for only 186/356 (52.25%) patients and 80 out of 
these 186 (43%) patients were acidotic. Mean BMI at diagnosis was 18.3±3.6 (BMI WHO z-score at 
diagnosis and at baseline was 0.46±1.2 and 0.53±1.3 respectively) and frequency of clinic visits 
from diagnosis ranged from 1 to 13.  (See Supplementary Table S2 for baseline characteristics by 
HbA1c tertiles) 
  
The fractional polynomial model 1 fitted to HbA1c measurements taken 0-24 months post T1D 
diagnosis revealed that the initial, high HbA1c levels of the cohort dropped rapidly after diagnosis 
due to initiation of insulin treatment. However, subsequently after around three months of diagnosis, 
the population mean HbA1c levels rose steadily above the then (2005-2015) NICE recommended 
targets and remained high throughout the entire duration of follow-up. The model 2 fitted to HbA1c 
measurements 3-24 months gave similar results for that period (Fig panel 1). 
 
We then examined the association of various predictor variables with HbA1c trajectories from 3 to 
24 months of T1D diagnosis. At the univariable level, pubertal age (12-18 years) at diagnosis, year 
of diagnosis pre 2011, non-white ethnicity, clinic site, frequency of clinic visits, insulin regimen type 
and higher HbA1c levels at diagnosis and during 0-3 months after diagnosis were significant 
predictors of higher mean HbA1c over the follow up period (Table 2).  
 
After adjustment for predictors that were statistically significant in univariable analyses, the following 
predictors of glycaemic control remained statistically significant in a multivariable analysis (Table 2): 
age at diagnosis (12-18 years), earlier years of diagnosis (pre 2011), non-white ethnicity, HbA1c 
during the 1st three months after diagnosis) and clinic site.   
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The results were similar when the multivariable analyses were repeated in the sensitivity analyses 
with predictors: HbA1c tertiles at baseline (Supplementary table S3a) and HbA1c at diagnosis 
(supplementary table S3b).  
 
Additional univariable and multivariable sensitivity analyses for predictor variables from 1-3 months 
after diagnosis consistently revealed the following as significant predictors of poor glycaemic control: 
year of diagnosis (pre-2011), clinic site, HbA1c and BMI (WHO z score) at 1-3 months after 
diagnosis.“ 
 
There was no effect modification when interaction with age at diagnosis, sex or clinic site were 
added to the mixed initial (with each predictor variable) and multivariable models. However, 
interaction with ethnicity by clinic site showed some significance in both univariable (p=0.04) and 
multivariable (p=0.05) analyses. The interaction year of diagnosis by gender seems to have an effect 
of borderline significance in multivariable analyses (p=0.04). Age at diagnosis by clinic interaction 
showed some significance (p=0.05) in the univariable analyses and p=0.03 in the sensitivity 
analyses when predictor HbA1c at diagnosis was added to the multivariable analyses 
(supplementary table S3b). 
 
We then examined the following predictors by including interactions with polynomial terms in time 
since diagnosis in the initial mixed models with each predictor variable: sex, age at T1D diagnosis, 
year of diagnosis, ethnicity, clinic site, insulin regimen, HbA1c level at diagnosis and baseline (also 
tertiles at baseline) and BMI (WHO) z score at baseline (Supplementary table S4). The interaction 
with polynomial time terms allowed for the shapes of the HbA1c trajectories to differ between the 
compared groups. The following predictors had significant interactions with polynomial time terms: 
age at diagnosis, HbA1c at diagnosis (Figure panel 2) and HbA1c at baseline. 
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Interaction between age at diagnosis and polynomial time terms showed that pre-pubertal (6-
11years) and pubertal children (12-18years) experienced a sharper increase in HbA1c after 3 
months than preschool (0-5years) aged children, leading to higher levels throughout the study period 
(p=0.001) (Figure panel 2a).  
 
There was a significant difference in HbA1c trajectories between those with low, moderate and high 
HbA1c levels at diagnosis (Figure panel 2b) and baseline (p=0.001 and p=0.01 respectively). All 
children had a similar starting point at 3 months but, the glycaemic control steadily deteriorated in 
those children with HbA1c levels above 7.5% (58 mmol/mol) at diagnosis or at baseline. But, there 
is some uncertainty in the HbA1c trajectory of those who had HbA1c levels <7.5% (<58mmol/mol) 
at diagnosis or at baseline as there were only 13 (5.14%) and 38 (10.67%) patients in these groups 
at diagnosis and baseline respectively and the diagnosis details of these patients could not be 
verified. However, we found that the difference between HbA1c trajectories was of significance 
(p=0.02) when the analyses were repeated by HbA1c tertiles at baseline (Supplementary figure 2)    
 
DISCUSSION 
Our longitudinal, retrospective, cohort study of glycaemic control during 3-24 months after T1D 
diagnosis in 356 children and adolescents of multi-ethnic backgrounds, receiving care; between 1 
January 2005 and 31 December 2015; at a network of three diabetes clinics located in East London, 
UK. We used fractional polynomial modelling to estimate the non-linear mean HbA1c trajectories to 
identify the predictors (socio-demographic, biological and clinical) of glycaemic control during the first 
2 years of T1D diagnosis. We found that the partial remission period ends at around 3 months from 
diagnosis, and that independent risk factors of poorer glycaemic control during the 2005-2015 study 
period were higher levels of HbA1c at baseline, higher age at diagnosis (12-18 years), non-white 
ethnicity, year of diagnosis (pre- year 2011) and clinic factors.  
 
15 
 
It is important to ensure good glycaemic control from T1D onset, but lack of evidence on predictors 
of glycaemic control restricts prediction of future glycaemic trends and risk of complications in 
children and young people, thus hampering the proactive prognosis and management of glycaemic 
control in high risk patients. Furthermore, glycaemic control is an important outcome and an 
exposure and/or mediator of later-life outcomes. Previously, NICE recommended HbA1c targets 
below 7.5% (58mmol/mol) (19). However, since year 2015, NICE recommends achieving a target 
of HbA1c levels of 6.5% (48mmol/mol) or below including during the honeymoon phase (period 
shortly after T1D diagnosis) when the existing beta cells of the pancreas continue to produce some 
insulin to help control blood glucose. Our study found that it was challenging for the cohort to achieve 
recommended blood glucose and HbA1c levels after the honeymoon period and during the first 24 
months of T1D diagnosis during the study period (2005-2015) as indicated by other studies (20, 21). 
 
In this cohort of young children and adolescents with T1D, we found that higher HbA1c levels (>9.5% 
i.e. >80mmol/mol) at diagnosis/baseline were associated with higher HbA1c levels during the first 
24 months of T1D diagnosis. Elevated HbA1c levels at diagnosis may be due to delayed access to 
medical treatment and/or delayed T1D diagnosis but evidence suggests that better glycaemic 
control can be achieved during this sensitive period through disease awareness and change of 
behaviors in diagnostic and care practice (22, 23).  
 
Children diagnosed at an older age (12 to 18 year olds) had significantly poorer glycaemic control 
during the study period. Adolescence has proven to be yet another sensitive period which influences 
formation of enduring behaviours and diabetes self -management habits (24).  This may relate to a 
complex interaction of factors such as increased insulin resistance, eating disorders, psychological 
disturbances and the psychosocial demands of adolescence leading to decreased adherence to 
management plans (25, 26).  
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Children diagnosed pre - 2011 had poorer glycaemic control which may be due to older diagnostic 
testing, treatment and recording strategies as reported by other studies (13, 27).  Additionally, it may 
indicate that being part of a network improved the glycaemic outcomes of the patients registered at 
the three clinics, as the three clinics became part of a network only from 2012. However, this is a 
causal hypothesis which the currently reported data and analyses cannot address. 
 
We also found that overweight or obese children had better glycaemic control, although this effect 
was statistically non-significant. This is likely to reflect the association of weight gain during T1D 
treatment with better adherence to insulin regimens and therefore BMI may represent an indirect 
marker of good glycaemic control. However, there is uncertainty in the HbA1c trajectory of 
underweight/thin children in our study as there were <10% children in this group. Evidence from 
other studies on the association of BMI with HbA1c is also inconclusive (28-30). Also, a small 
minority of patients may have been misclassified during the study period and may have had T2D, 
MODY or secondary diabetes.  
 
Non-white ethnicity was associated with elevated HbA1c levels. This association is consistent with 
other studies and may be due to biological, cultural and lifestyle differences, sub-optimal treatment 
prescription or reluctance to try new therapy (31-33). Also, some ethnicities may have an inherent 
genetic predisposition to adverse health outcomes from T1D (34). The role of clinic in improving  
glycaemic control in children with T1D (particularly ethnic minorities) and whether more frequent 
clinic visits would result in better care and adherence to treatment among the T1D patients from 
ethnic minority remains unclear.  
 
However, we did find that patients at one of the clinics had better glycaemic control than others and 
that more frequent clinic visits (univariable analyses) were associated with higher HbA1c levels. 
More frequent appointments for children with poor control may have been offered in some clinics. 
Other studies have indicated associations with glycaemic control and clinic related factors (2, 28, 
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35). Some studies have also highlighted the active role of diabetes teams in achieving glycaemic 
targets (36, 37). Frequency of clinic attendance may be high in those patients living closer to the 
diabetes clinics. Poor or non-attendance is associated with elevated diabetes complications risk due 
to non-adherence to treatment in the high risk groups (38). 
 
Details of insulin regimen such as injection frequency, pump treatment, dosage and treatment 
changes were missing which meant that we were restricted in our investigations of this variable 
against our research objectives, although, pump regimen (univariable analyses) was associated 
with lower HbA1c levels. However, sensitivity analysis with and without adjusting for insulin regimen 
did not affect our conclusions. It would be useful to investigate the benefits of intensive insulin 
treatment earlier on in the course of the disease management and whether early HbA1c levels tracks 
in later years and reduces the risk of vascular complications.  
 
In our study we found that sex showed no association (univariable analyses) with glycaemic control 
although interaction with year of diagnosis by sex (univariable and multivariable analyses) showed 
some association. This is contrary to the findings of some studies (5, 13, 30); whilst there are others 
who have reported no association (28, 35) between sex and HbA1c levels.  
 
No association was seen between pH at diagnosis (proxy for DKA) and HbA1c levels during the 3-
24 months from T1D diagnosis. Although this was also the conclusion of some studies (28, 30, 35), 
others have shown an association (39-41). It was not clear if the general practitioners (GP’s) 
managed the T1D symptoms in any of these patients prior to referral to the diabetes clinics for 
specialist care.  We did not have access to GP prescription data to confirm if any form of glycaemic 
control started prior to clinic diagnosis date although it would be extremely unusual in the UK for a 
GP to commence insulin treatment in a child with diabetes.  
 
STRENGTHS AND LIMITATIONS 
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Historically, mixed effects modelling have been used to describe trajectories of repeated outcomes 
within and between clustered individuals. But since glycaemic trajectories are often non-monotonic 
and non-linear, they require more flexible models to accurately investigate the factors which influence 
the HbA1c levels or the outcomes it is associated with. To our knowledge this is the first longitudinal 
study to investigate predictors of HbA1c during the first 24 months of T1D duration using mixed 
effects multilevel models with fractional polynomial time terms which allowed flexibility and parsimony 
in the modelling of non-linear trajectories. The application of fractional polynomials requires the 
comparison of many models for model selection and represents a situation of multiple testing. The 
modest sample size was suitable for the two step approach using fractional polynomials in multilevel 
modelling. However, the sample size limitation precluded the enhancement of complexity of fitting 
models with all covariates. Assessment of predictors of HbA1c was performed in a two-step 
approach, with polynomial terms selected in the first step and predictor selection performed in the 
second step. The effect estimates of present models may be biased due to the two-step procedure, 
and no adjustment has been made for multiple testing. Data were abstracted from routinely collected 
electronic medical records, thus limiting selection and recall bias. It was not possible to ascertain that 
the primary outcome or exposure was not associated with loss to follow-up. The total sample size 
was modest but exceeded the minimum (N>100) suggested for multilevel modelling and may have 
limited the power to detect weaker associations The study cohort was rich in ethnic diversity and an 
unusually high proportion of socially deprived population, which enabled us to study these predictors 
in greater detail but was also a limitation since there was less contrast.  
 
Data was limited to patients receiving care between 2005 and 2015 at three diabetes clinics which 
formed a network in 2012. So the methods of data collection and recording may have differed and 
changed over the study period and may not be generalizable to other populations. The data used 
were from a dataset maintained for ongoing clinical use across the 3 clinic sites, and, as with most 
clinical datasets, was not subject to the detailed data checking that would be expected in a research 
dataset. We verified data where possible in association with the clinic physicians. However it was not 
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practicable to examine and verify each individual clinical record. Additionally, it was not possible to 
investigate whether the disparity in the number of clinic visits and treatment across the study 
population was due to individual and/or clinic factors. This is a retrospective analysis of an 
observational study and residual confounding cannot be ruled out. Details of laboratory methods and 
instruments used across clinics between 2005 and 2015 could not be confirmed.  
 
CONCLUSIONS  
Our study identified higher HbA1c levels at baseline, non- white ethnicity, clinic site, BMI and year 
of diagnosis as major risk factors of poor glycaemic control during the first 24 months of children 
diagnosed with T1D. Since higher HbA1c at T1D diagnosis is associated with poorer subsequent 
HbA1c levels and is associated with increased risk of developing complications, these findings could 
help clinicians, policy makers and researchers better understand the characteristics of type 1 
diabetes and encourage quick identification of high risk patients for consideration of appropriate 
individualized treatment strategy to meet the HbA1c targets during the 24 months following the 
diagnosis of T1D. These findings will also help explore the underlying explanations for poor 
glycaemic outcomes so further efforts are made to overcome these differences.  
 
FUTURE RESEARCH 
Further research into the reasons for differences in HbA1c outcomes is required. Also predictors of 
glycaemic control in the first 3 months of diagnosis and beyond 2 years of diagnosis need further 
investigation. 
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FIGURE PANEL 1: Estimated HbA1c trajectories based on fractional polynomials 
       
 Fig 1a: Estimated HbA1c trajectory of 253 patients followed from diagnosis                       Fig 1b: Estimated HbA1c trajectory of 335 patients followed from baseline   
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FIGURE PANEL 2: Estimated HbA1c trajectories based on fractional polynomials by age at diagnosis or HbA1c at diagnosis  
 
       
 Fig 2a: Age at diagnosis                                                                         Fig 2b: HbA1c at diagnosis                               
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Table 1: Baseline# characteristics of study population by HbA1c categories. Data are mean (±SD) or counts (%) 
Characteristic Total HbA1c levels at baseline (mmol/mol) P value  
(for difference by HbA1c at 
baseline) 
<58mmol/mol 58-80mmol/mol >80mmol/mol 
Sex  
Male 
Female 
N=356 
169 (47.47%) 
187 (52.53%) 
N=38 (10.67%) 
25 (65.79%) 
13 (34.21%) 
N=117 (32.87%) 
63 (53.85%) 
54 (46.15%) 
N=201 (56.46%) 
81 (40.30%) 
120 (59.70%) 
0.01* 
Age at diagnosis (years) N=356 
8.9±4.3 
N=38 
9.5±4.7 
N=117 
8.07±4.5 
N=201  
9.3±4.1 
0.03* 
Age at diagnosis  
0-5yrs 
6-11yrs 
12-18yrs 
N=356 
106 (29.78%) 
143 (40.17%) 
107 (30.06%) 
N=38 
11 (28.95%) 
13 (34.21%) 
14 (36.84%) 
N=117 
44 (37.61%) 
40 (34.19%) 
33 (28.21%) 
N=201 
51 (25.37%) 
90 (44.78%) 
60 (29.85%) 
0.14† 
Period of T1D onset 
Year 2005 to 2010 
Year 2011 - 2015 
N=356 
181 (50.84%) 
175 (49.16%) 
N=38 
11 (28.95%) 
27 (71.05%) 
N=117 
56 (47.86%) 
61 (52.14%) 
N=201 
114 (56.72%) 
87 (43.28%) 
0.01* 
Season of T1D onset 
Spring 
Summer 
Autumn 
Winter 
N=356 
93 (26.12%) 
75 (21.07%) 
82 (23.03%) 
106 (29.78%) 
N=38 
11 (28.95%) 
7 (18.42%) 
7 (18.42%) 
13 (34.21%) 
N=117 
38 (32.48%) 
13 (11.11%) 
32 (27.35%) 
34 (29.06%) 
N=201 
44 (21.89%) 
55 (27.36%) 
43 (21.39%) 
59 (29.35%) 
0.02† 
Ethnicity  
1 White v/s 
2 Non white 
Non-white sub groups 
a) Mixed 
b) Black 
c) Asian/other 
N=351 
125 (35.61%) 
226 (64.39%) 
 
35 (9.97%) 
79 (22.51%) 
112 (31.91%) 
N=38 (10.82%) 
14 (36.84%) 
24 (63.16%) 
 
2 (5.26%) 
9 (23.68%) 
13 (34.21%) 
N=116 (33.05%) 
51 (43.97%) 
65 (56.03%) 
 
13 (11.21%) 
27 (23.28%) 
25 (21.55%) 
N=197 (56.13%) 
60 (30.46%) 
137 (69.54%) 
 
20 (10.15%) 
43 (21.83%) 
74 (37.56%) 
0.05† 
Indices of Multiple Deprivation 
Most deprived 
Moderate 
Least deprived 
N=354 
187 (52.82%) 
127 (35.88%) 
40 (11.30%) 
N=38 (10.73%) 
18 (47.37%) 
13 (34.21%) 
7 (18.42%) 
N=117 (33.05%) 
60 (51.28%) 
41 (35.04%) 
16 (13.68%) 
N=199 (56.22%) 
109 (54.77%) 
73 (36.68%) 
17 (8.54%) 
0.39† 
No of patients at clinics 
1  
2  
3  
N=356 
36 (10.11%) 
112 (31.46%) 
208 (58.43%) 
N=38 
12 (31.58%) 
9 (23.68%) 
17 (44.74%) 
N=117 
15 (12.82%) 
36 (30.77%) 
66 (56.41%) 
N=201 
9 (4.48%) 
67 (33.33%) 
125 (62.19%) 
0.01† 
Insulin regimen 
1-2 inj./day 
>=3 inj. per day 
Pump 
N=341 
92 (26.98%) 
233 (68.33%) 
16 (4.69%) 
N=37 (10.85%) 
9 (24.32%) 
25 (67.57%) 
3 (8.11%) 
N=112 (32.84%) 
31 (27.68%) 
74 (66.07%) 
7 (6.25%) 
N=192 (56.31%) 
52 (27.08%) 
134 (69.79%) 
6 (3.13%) 
0.60† 
HbA1c at diagnosis (mmol/mol) N=253 
92.9 ±23.10 
N=13 (5.14%) 
49.69±5.44 
N=62 (24.50%) 
69.60±6.58 
N=178 (70.36%) 
104.17±16.96 
0.01* 
HbA1c at baseline (mmol/mol) N=356  N=38 (10.67%) N=117 (32.87%) N=201 (56.46%) 0.01* 
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85.79±23.75 49.89±6.03 68.98±6.29 102.36±16.89 
HbA1c at 1 to 3 months of diagnosis 
(mmol/mol) 
N=242 
66.11 ±14.76 
N=29 (11.98%) 
49.72±6.19 
N=91 (37.61%) 
63.40±9.67 
N=122 (50.41%) 
72.03±15.82 
0.001* 
HbA1c at 2 to 3 months of diagnosis 
(mmol/mol) 
N=127 
61.37 ±15.00 
N=19 (5.14%) 
50.89±5.71 
N=44 (24.50%) 
59.52±9.91 
N=64 (70.36%) 
65.75±17.85 
0.001* 
pH at diagnosis N=186 
7.27±0.16 
N=9 (4.84%) 
7.33±0.19 
N=40 (21.50%) 
7.33±0.13 
N=137 (73.66%) 
7.25±0.16 
0.02* 
pH at diagnosis 
Normal 7.3-7.45 
Acidotic <7.3 
Alkalotic >7.45 
N=186 
98 (52.69%) 
80 (43.01%) 
8 (4.30%) 
N=9 
5 (55.56%) 
2 (22.22%) 
2 (22.22%) 
N=40 
31 (77.50%) 
8 (20.00%) 
1 (2.50%) 
N=137 
62 (45.26%) 
70 (51.09%) 
5 (3.65%) 
0.01† 
BMI at diagnosis (kg/m2) N=232 
18.29±3.62 
N=11 (4.74%) 
21.26±5.48 
N=56 (24.14%) 
18.03±2.83 
N=165 (71.12%) 
18.18±3.65 
0.01* 
BMI WHO z-score at baseline 
Thin 
Normal weight 
Obese/overweight 
N=330 
70 (21.21%) 
103 (31.21%) 
157 (47.58%) 
N=33 (10.00%) 
 5 (7.14%) 
6 (5.83%) 
22 (14.01%) 
N=109 (33.03%) 
19 (27.14%) 
30 (29.13%) 
60 (38.22%) 
N=188 (56.97%) 
46 (65.71%) 
67 (63.05%) 
75 (47.77%) 
0.02† 
#Baseline: Period within 3 months of T1D diagnosis; N: Number of patients; †: Global Wald test (χ²); *: Wald test (χ²); HbA1c: Glycated hemoglobin; pH: measure of acidity;  
BMI: Body mass index; WHO: World health organization 
 
Table 2: Predictors of glycaemic control in children and adolescents from 3 to 24 months post-T1D diagnosis (MVA with predictor HbA1c at baseline) 
Predictor Univariable analysis Multivariable analysis (MVA) without 
interaction terms 
MVA (with predictors showing significant 
interaction with sex, age at diagnosis or 
clinic)  
 N Estimate (95%CI) p-value N Estimate (95%CI) p-value N Estimate (95%CI) p-value 
Sex (ref female) 335 0.46 (-2.79 to 3.72 ) 0.78*       
Age at diagnosis (Ref 0-5yrs) 
6-11yrs 
12-18yrs 
335  
0.96 (-2.92 to 4.84) 
5.84 (1.65 to 10.02) 
0.01† 
 
330  
0.59 (-3.11 to 4.28) 
5.05 (1.07 to 9.03) 
0.02† 330  
0.44 (-3.23 to 4.11) 
4.49 (0.53 to 8.45) 
0.04† 
Year of Diagnosis (Ref pre 2011) 
2011 – 2015 
335  
-7.47 (-10.63 to -4.31) 
0.001* 330  
-6.09 (-9.17 to -3.01) 
0.001* 330  
-9.43 (-13.63 to -5.23) 
0.001* 
Season of diagnosis (Ref Spring) 
Summer 
Autumn 
Winter 
335  
1.71 (-3.08 to 6.51) 
1.82 (-2.82 to 6.47) 
3.58 (-0.73 to 7.89) 
0.45†       
Ethnicity (Ref White) 
Non white 
331  
5.46 (2.07 to 8.85) 
 
0.002* 
330  
3.89 (0.66 to 7.13) 
0.02* 330  
5.37 (1.28 to 9.45) 
0.01* 
IMD (Ref 1 most deprived) 
2 (moderate) 
3 (least deprived) 
333  
0.89 (-2.65 to 4.42) 
-2.06 (-7.47 to 3.34) 
0.59† 
 
 
      
Clinic (ref clinic 3) 
1 
335  
-0.53 (-6.05 to 4.99) 
0.001† 
 
330  
2.43 (-3.12 to 7.97) 
0.02† 330  
11.48 (2.42 to 20.55) 
0.01† 
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2 6.55 (3.08 to 10.02)  4.66 (1.34 to 7.98) 6.09 (0.12 to 12.06) 
Number of clinic visits1 335 0.22 (0.03 to 0.41) 0.02*       
Insulin regimen(Ref >=3 inj. per day) 
1-2 inj./day 
Pump 
333  
0.62 (-2.13 to 3.36) 
-7.64 (-13.18 to -2.10) 
0.02†       
HbA1c at diagnosis 238 0.15 (0.07 to 0.23) 0.001*       
HbA1c at diagnosis (ref <58 mmol/mol) 
58 to 80  
>80 mmol/mol 
238  
5.74 (-3.60 to 15.09) 
10.36 (1.59 to 19.14) 
0.02†       
HbA1c at baseline 334 0.25 (0.17 to 0.33) 0.001*       
HbA1c at baseline (ref <58 mmol/mol) 
58 to 80  
>80 mmol/mol 
334  
2.47 (-2.57 to 7.51) 
8.80 (3.84 to 13.76) 
0.001† 330  
3.02 (-1.88 to 7.93) 
7.55 (2.61 to 12.48) 
0.003† 330  
3.07 (-1.75 to 7.90) 
8.21 (3.30 to 13.12) 
0.001† 
HbA1c during 1 to 3 months after diagnosis 230 0.37 (0.25 to 0.49) 0.001*       
HbA1c during 1 to 3 months after diagnosis (ref <58 
mmol/mol) 
58 to 80  
>80 mmol/mol 
230  
 
7.19 (3.01 to 11.36) 
14.26 (8.88 to 19.63) 
0.001†       
HbA1c at 2 to 3 months after diagnosis 124 0.56 (0.40 to 0.71) 0.001*       
HbA1c at 2 to 3 months after diagnosis (ref <58 
mmol/mol) 
58 to 80  
>80 mmol/mol 
124  
 
12.87 (7.84 to 17.91) 
21.15 (13.05 to 29.26) 
0.001†       
pH at diagnosis (Ref normal pH 7.3-7.45) 
Acidotic <7.3 
Alkalotic >7.45 
175  
1.80 (-2.84 to 6.44) 
2.65 (-8.43 to 13.74) 
0.71†       
BMI (WHO) z score at baseline (ref normal weight) 
Overweight/obese 
Thin 
309  
-2.27 (-6.26 to 1.73) 
1.41 (-3.38 to 6.20) 
0.22†       
Year of diagnosis # sex (Ref Females) 
Pre 2011 # Males 
2011 – 2015 # Males 
      330  
-1.88 (-6.07 to 2.31) 
5.38 (0.91 to 9.84) 
0.04† 
Ethnicity # clinic (Ref white # clinic 3) 
Non-white # Clinic 1 
Non-white # Clinic 2 
      330  
-13.84 (-24.94 to -2.75) 
-2.49 (-9.63 to 4.66) 
0.05† 
†: Global Wald test (χ²); *: Wald test (χ²); Ref: reference group; IMD: Indices of multiple deprivation; 1: clinic visits (range 2-13); HbA1c: Glycated hemoglobin; pH: measure of acidity;  
BMI: Body mass index; WHO: World health organization. All models include √ and log*√ functions of time as both fixed and random effects. 
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Supplementary figure panel 1a: Histograms showing patterns of visits to clinic during 0-3 months after T1D diagnosis 
 
   
  Clinic 1           Clinic 2         Clinic 3 
 
Supplementary figure panel 1b: Histograms showing patterns of visits to clinic after 3 months of T1D diagnosis  
 
    
  Clinic 1           Clinic 2         Clinic 3 
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Supplementary figure 2: Predictor HbA1c tertiles at baseline showing significant differences between HbA1c trajectories over time                       
     
    Fig 2: HbA1c tertiles within 3 months of diagnosis 
 
Supplementary Table S1a: Fractional Polynomial three-dimension model fit comparison algorithm for period 0-24 months post T1D diagnosis  
Fractional Polynomial model  Index for comparison 
 -2LL AIC BIC 
Linear model 14398.42 14408.42 14435.43 
Model with one polynomial term 13887.14 13897.14 13924.15 
Model with two polynomial terms 13571.56 13585.56 13623.37 
Model with three polynomial terms 13507.02 13525.02 13573.62 
 
Supplementary Table S1b: Fractional Polynomial three-dimension model fit comparison algorithm for period 3-24 months post T1D diagnosis  
Fractional Polynomial model  Index for comparison 
 -2LL AIC BIC 
Linear model 13221.92 13231.92 13258.89 
Model with one polynomial term 13125.53 13135.53 13162.50 
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Model with two polynomial terms 13106.62 13120.62 13158.38 
Model with three polynomial terms 13100.65 13118.65 13167.20 
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Supplementary Table S2: Baseline# characteristics of study population by HbA1c tertiles. Data are mean (±SD) or counts (%) 
Characteristic Total HbA1c tertiles at baseline (mmol/mol) P value  
(for difference by HbA1c 
tertiles at baseline) 
Tertile 1 
(<74mmol/mol) 
Tertile 2 
(74-95mmol/mol) 
Tertile 3 
(>95mmol/mol) 
Sex  
Male 
Female 
N=356 
169 (47.47%) 
187 (52.53%) 
N=120 (33.71%) 
66 (65.00%) 
54 (45.00%) 
N=120 (33.71%) 
61 (50.83%) 
59 (49.17%) 
N=116 (32.58%) 
42 (36.21%) 
74 (63.79%) 
0.01* 
Age at diagnosis (years) N=356 
8.9±4.3 
N=120 
8.7±4.6 
N=120 
8.2±4.5 
N=116  
9.9±3.8 
0.01* 
Age at diagnosis  
0-5yrs 
6-11yrs 
12-18yrs 
N=356 
106 (29.78%) 
143 (40.17%) 
107 (30.06%) 
N=120 
39 (32.50%) 
42 (35.00%) 
39 (32.50%) 
N=120 
47 (39.17%) 
42 (35.00%) 
31 (25.83%) 
N=116 
20 (17.24%) 
59 (50.86%) 
37 (31.90%) 
0.003† 
Period of T1D onset 
Year 2005 to 2010 
Year 2011 - 2015 
N=356 
181 (50.84%) 
175 (49.16%) 
N=120 
50 (41.67%) 
70 (58.33%) 
N=120 
63 (52.50%) 
57 (47.50%) 
N=116 
68 (58.62%) 
48 (41.38%) 
0.03* 
Season of T1D onset 
Spring 
Summer 
Autumn 
Winter 
N=356 
93 (26.12%) 
75 (21.07%) 
82 (23.03%) 
106 (29.78%) 
N=120 
42 (35.00%) 
14 (11.67%) 
26 (21.67%) 
38 (31.67%) 
N=120 
28 (23.33%) 
30 (25.00%) 
29 (24.17%) 
33 (27.50%) 
N=116 
23 (19.83%) 
31 (26.72%) 
27 (23.28%) 
35 (30.17%) 
0.03† 
Ethnicity  
1 White v/s 
2 Non white 
Non-white sub groups 
a) Mixed 
b) Black 
c) Asian/other 
N=351 
125 (35.61%) 
226 (64.39%) 
 
35 (9.97%) 
79 (22.51%) 
112 (31.91%) 
N=119 (33.90%) 
53 (42.40%) 
66 (29.20%) 
 
10 (28.57%) 
29 (36.71%) 
27 (24.11%) 
N=119 (33.90%) 
43 (34.40%) 
76 (33.63%) 
 
17 (48.57%) 
21 (26.58%) 
38 (33.93%) 
N=113 (32.19%) 
29 (23.20%) 
84 (37.17%) 
 
8 (22.86%) 
29 (36.71%) 
47 (41.96%) 
0.01† 
Indices of Multiple Deprivation 
Most deprived 
Moderate 
Least deprived 
N=354 
187 (52.82%) 
127 (35.88%) 
40 (11.30%) 
N=120 (33.90%) 
63 (52.50%) 
39 (32.50%) 
18 (15.00%) 
N=118 (33.33%) 
50 (42.37%) 
55 (46.61%) 
13 (11.02%) 
N=116 (32.77%) 
74 (63.79%) 
33 (28.45%) 
9 (7.76%) 
0.01† 
No of patients at clinics 
1  
2  
3  
N=356 
36 (10.11%) 
112 (31.46%) 
208 (58.43%) 
N=120 
24 (20.00%) 
38 (31.67%) 
58 (48.33%) 
N=120 
8 (6.67%) 
36 (30.00%) 
76 (63.33%) 
N=116 
4 (3.45%) 
38 (32.76%) 
74 (63.79%) 
0.01† 
Insulin regimen 
1-2 inj./day 
>=3 inj. per day 
Pump 
N=341 
92 (26.98%) 
233 (68.33%) 
16 (4.69%) 
N=116 (34.02%) 
28 (24.14%) 
79 (68.10%) 
9 (7.76%) 
N=114 (33.43%) 
32 (28.07%) 
75 (65.79%) 
7 (6.14%) 
N=111 (32.55%) 
32 (28.83%) 
79 (71.17%) 
0 (0.00%) 
0.07† 
HbA1c at diagnosis (mmol/mol) N=253 
92.9 ±23.10 
N=53 (20.95%) 
61.66±8.25 
N=89 (35.18%) 
85.12±6.58 
N=111 (43.87%) 
114.05±13.75 
0.01* 
HbA1c at baseline (mmol/mol) N=356  N=120 N=120 N=116  0.01* 
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78.44±19.24 59.04±8.50 78.74±7.75 98.21±14.79 
HbA1c at 2 to 3 months after diagnosis 
(mmol/mol) 
N=127  
61.37±15.00 
N=51 (40.16%) 
55.08±8.36 
N=39 (30.71%) 
65.05±14.57 
N=37 (29.13%) 
66.16±19.29 
0.001* 
pH at diagnosis N=186 
7.27±0.16 
N=35 (18.82%) 
7.32±0.14 
N=66 (35.48%) 
7.27±0.16 
N=85 (45.70%) 
7.25±0.17 
0.07* 
pH at diagnosis 
Normal 7.3-7.45 
Acidotic <7.3 
Alkalotic >7.45 
N=186 
98 (52.69%) 
80 (43.01%) 
8 (4.30%) 
N=35 
26 (74.29%) 
7 (20.00%) 
2 (5.71%) 
N=66 
31 (46.97%) 
32 (48.48%) 
3 (4.55%) 
N=85 
41 (48.24%) 
41 (48.24%) 
3 (3.53%) 
0.05† 
BMI at diagnosis (kg/m2) N=232 
18.29±3.62 
N=47 (20.26%) 
18.80±3.78 
N=85 (36.64%) 
17.74±3.14 
N=100 (43.10%) 
18.52±3.89 
0.18* 
BMI WHO z-score at baseline 
Thin 
Normal weight 
Obese/overweight 
N=330 
70 (21.21%) 
103 (31.21%) 
157 (47.58%) 
N=109 (33.03%) 
18 (16.51%) 
29 (26.61%) 
62 (56.88%) 
N=116 (35.15%) 
29 (25.00%) 
34 (29.31%) 
53 (45.69%) 
N=105 (31.82%) 
23 (21.21%) 
40 (38.10%) 
42 (40.00%) 
0.10† 
#Baseline: Period within 3 months of T1D diagnosis; N: Number of patients; †: Global Wald test (χ²); *: Wald test (χ²); HbA1c: Glycated hemoglobin; pH: measure of acidity;  
BMI: Body mass index; WHO: World health organization 
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Supplementary Table S3a: Predictors of glycaemic control in children and adolescents from 3 to 24 months post-T1D diagnosis (MVA with predictor HbA1c 
tertiles at baseline)  
 
Predictor Univariable analysis Multivariable analysis (MVA) without 
interaction terms 
MVA (with predictors showing significant 
interaction with sex, age at diagnosis or clinic)  
 N Estimate (95%CI) p-value N Estimate (95%CI) p-value N Estimate (95%CI) p-value 
Sex (Ref female) 335 0.46 (-2.79 to 3.72 ) 0.78*       
Age at diagnosis (Ref 0-5yrs) 
6-11yrs 
12-18yrs 
335  
0.96 (-2.92 to 4.84) 
5.84 (1.65 to 10.02) 
0.01† 
 
331  
1.15 (-2.60 to 4.90) 
5.49 (1.50 to 9.49) 
0.01† 331  
1.05 (-2.68 to 4.78) 
5.10 (1.12 to 9.08) 
0.03† 
Year of Diagnosis (Ref pre 2011) 
2011 – 2015 
335  
-7.47 (-10.63 to -4.31) 
0.001* 331  
-6.36 (-9.47 to -3.26) 
0.001* 331  
-9.16 (-13.40 to -4.92) 
0.001* 
Season of diagnosis (Ref Spring) 
Summer 
Autumn 
Winter 
335  
1.71 (-3.08 to 6.51) 
1.82 (-2.82 to 6.47) 
3.58 (-0.73 to 7.89) 
0.45†       
Ethnicity (Ref White) 
Non white 
331  
5.46 (2.07 to 8.85) 
 
0.001* 
331  
4.12 (0.87 to 7.38) 
0.01* 331  
6.03 (1.90 to 10.15) 
0.004* 
IMD (Ref 1 most deprived) 
2 (moderate) 
3 (least deprived) 
333  
0.89 (-2.65 to 4.42) 
-2.06 (-7.47 to 3.34) 
0.59† 
 
 
      
Clinic (Ref clinic 3) 
1 
2 
335  
-0.53 (-6.05 to 4.99) 
6.55 (3.08 to 10.02)  
0.001† 
 
331  
1.96 (-3.59 to 7.51) 
5.14 (1.77 to 8.50) 
0.01† 331  
11.08 (2.11 to 20.04) 
7.35 (1.24 to 13.45) 
0.01† 
Number of clinic visits1 335 0.22 (0.03 to 0.41) 0.02*       
Insulin regimen(Ref >=3 inj. per day) 
1-2 inj./day 
Pump 
333  
0.62 (-2.13 to 3.36) 
-7.64 (-13.18 to -2.10) 
0.02†       
HbA1c tertiles at baseline (Tertile 1 mmol/mol) 
Tertile 2  
Tertile 3 
335  
3.80 (-0.16 to 7.75) 
5.79 (1.88 to 9.71) 
0.01† 331  
3.55 (-0.27 to 7.37) 
4.32 (0.38 to 8.26) 
0.07† 331  
3.96 (0.17 to 7.75) 
5.02 (1.07 to 8.96) 
0.03† 
pH at diagnosis (Ref normal pH 7.3-7.45) 
Acidotic <7.3 
Alkalotic >7.45 
175  
1.80 (-2.84 to 6.44) 
2.65 (-8.43 to 13.74) 
0.71†       
BMI (WHO) z score at baseline (Ref normal 
weight) 
Overweight/obese 
Thin 
309  
 
-2.27 (-6.26 to 1.73) 
1.41 (-3.38 to 6.20) 
0.22†       
Year of diagnosis # sex (Ref Females) 
Pre 2011 # Males 
2011 – 2015 # Males 
      331  
-1.68 (-5.90 to 2.55) 
4.45 (-0.04 to 8.93) 
0.11† 
Ethnicity # clinic (Ref white # clinic 3) 
Non-white # Clinic 1 
Non-white # Clinic 2 
      331  
-14.09 (-25.10 to -3.09) 
-3.49 (-10.75 to 3.78) 
0.04† 
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†: Global Wald test (χ²); *: Wald test (χ²); Ref: reference group; IMD: Indices of multiple deprivation; 1: clinic visits (range 2-13); HbA1c: Glycated hemoglobin; pH: measure of acidity;  
BMI: Body mass index; WHO: World health organization. All models include √ and log*√ functions of time as both fixed and random effects 
 
Supplementary Table S3b: Predictors of glycaemic control in children and adolescents from 3 to 24 months post-T1D diagnosis (MVA with predictor HbA1c at 
diagnosis) 
  
Predictor Univariable analysis Multivariable analysis (MVA) without 
interaction terms 
MVA (with predictors showing significant 
interaction with sex, age at diagnosis or clinic)  
 N Estimate (95%CI) p-value N Estimate (95%CI) p-value N Estimate (95%CI) p-value 
Sex (ref female) 238 0.82 (-3.09 to 4.73 ) 0.68*       
Age at diagnosis (Ref 0-5yrs) 
6-11yrs 
12-18yrs 
238  
1.99 (-2.64 to 6.64) 
6.30 (1.16 to 11.45) 
0.05† 
 
234  
1.72 (-2.75 to 6.19) 
6.05 (1.11 to 10.99) 
0.04† 234  
2.38 (-2.81 to 7.56) 
9.65 (3.84 to 15.47) 
0.003† 
Year of Diagnosis (Ref pre 2011) 
2011 – 2015 
238  
-8.05 (-11.82 to -4.28) 
0.001* 234  
-6.84 (-10.58 to -3.09) 
0.001* 234  
-7.25 (-10.95 to -3.55) 
0.001* 
Season of diagnosis (Ref Spring) 
Summer 
Autumn 
Winter 
238  
2.41 (-3.19 to 8.01) 
4.37 (-1.17 to 9.91) 
3.51 (-1.69 to 8.70) 
0.42†       
Ethnicity (Ref White) 
Non white 
234  
5.96 (1.85 to 10.07) 
 
0.005* 
234  
5.24 (1.34 to 9.14) 
0.01* 234  
5.46 (1.63 to 9.28) 
0.01* 
IMD (Ref 1 most deprived) 
2 (moderate) 
3 (least deprived) 
236  
-1.13 (-5.35 to 3.09) 
-2.29 (-9.24 to 4.65) 
0.75† 
 
 
      
Clinic (ref clinic 3) 
1 
2 
238  
1.83 (-7.64 to 11.30) 
6.75 (2.52 to 10.97)  
0.008† 
 
234  
2.70 (-7.01 to 12.40) 
3.93 (-0.19 to 8.05) 
0.17† 234  
-9.11 (-30.94 to 12.72) 
9.96 (2.05 to 17.87) 
0.03† 
Insulin regimen(Ref >=3 inj. per day) 
1-2 inj./day 
Pump 
236  
-0.14 (-3.33 to 3.04) 
-7.20 (-13.53 to -0.86) 
0.08†       
HbA1c at diagnosis 238 0.15 (0.07 to 0.23) 0.001*       
HbA1c at diagnosis (ref <58 mmol/mol) 
58 to 80  
>80 mmol/mol 
238  
5.74 (-3.60 to 15.09) 
10.36 (1.59 to 19.14) 
0.02† 234  
5.69 (-3.35 to 14.74) 
9.05 (0.50 to 17.61) 
0.05† 234  
4.13 (-4.81 to 13.06) 
7.06 (-1.44 to 15.56) 
0.15† 
pH at diagnosis (Ref normal pH 7.3-7.45) 
Acidotic <7.3 
Alkalotic >7.45 
175  
1.80 (-2.84 to 6.44) 
2.65 (-8.43 to 13.74) 
0.71†       
BMI (WHO) z score at diagnosis (Ref normal weight) 
Overweight/obese 
Thin 
217  
-1.59 (-6.38 to 3.19) 
0.54 (-5.29 to 6.37) 
0.68†       
Age at diagnosis # clinic (Ref 0-5yrs  # clinic 3) 
6-11yrs # Clinic 1 
6-11yrs # Clinic 2 
12-18yrs # Clinic 1 
      234  
29.87 (0.71 to 59.03) 
-5.33 (-15.04 to 4.38) 
-6.01 (-18.78 to 30.80) 
0.03† 
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12-18yrs # Clinic 2 -12.69 (-23.49 to -1.89) 
†: Global Wald test (χ²); *: Wald test (χ²); Ref: reference group; IMD: Indices of multiple deprivation; HbA1c: Glycated hemoglobin; pH: measure of acidity; BMI: Body mass index; WHO: World health 
organization. All models include √ and log*√ functions of time as both fixed and random effects. 
 
 
Supplementary Table S4: Analysis of interactions between the predictor variable and the polynomial time functions 
Predictor N Estimated coefficients p- value* for 
difference 
between 
trajectories 
Constant  √t √t*logt 
Sex (Ref Female) 
Male 
335 8.30 (-12.66 to 29.27) 
6.14 (-23.90 to 36.17) 
60.40 (38.78 to 82.03) 
54.64 (32.41 to 76.87) 
-22.74 (-34.22 to -11.26) 
-19.02 (-30.95 to -7.10) 
0.87 
Age at diagnosis (Ref <6 years) 
6-11 years  
12-18 years 
335 48.89 (21.48 to 76.30) 
-58.27 (-93.78 to -22.77) 
-45.12 (-84.98 to -5.25) 
15.71 (-12.53 to 43.94) 
77.96 (54.65 to 101.26) 
69.95 (40.06 to 99.83) 
-3.86 (-18.91 to 11.18) 
-30.79 (-43.12 to -18.46) 
-23.48 (-39.61 to -7.34) 
0.001 
Year of Diagnosis (Ref pre 2011) 
2011 - 2015 
335 8.11 (-22.18 to 38.40) 
7.81 (-11.96 to 27.58) 
64.77 (44.32 to 85.23) 
48.96 (25.31 to 72.61) 
-25.63 (-36.50 to -14.77) 
-15.53 (-28.24 to -2.82) 
0.39 
Ethnicity (Ref White) 
Non white 
331 -6.28 (-33.14 to 20.58) 
25.85 (-6.55 to 58.24) 
72.29 (44.57 to 100.01) 
51.04 (32.32 to 69.76) 
-28.30 (-43.07 to -13.52) 
17.73 (-27.72 to -7.74) 
0.45 
Clinic (Ref clinic 3) 
1 
2 
335 7.60 (-12.48 to 27.67) 
54.06 (-9.34 to 117.47) 
0.78 (-30.77 to 32.32) 
59.18 (38.46 to 79.91) 
3.15 (-58.73 to 65.04) 
65.33 (40.19 to 90.47) 
-22.20 (-33.27 to -11.14) 
8.84 (-23.77 to 41.46) 
-24.58 (-38.04 to -11.12) 
0.44 
Insulin regimen (Ref >=3 inj. per day) 
1-2 inj./day 
Pump 
333 13.95 (-4.21 to 32.12) 
-13.60 (-48.84 to 21.64) 
31.46 (-57.83 to 120.75) 
55.47 (36.70 to 74.24) 
70.17 (39.58 to 100.77) 
15.46 (-74.03 to 104.95) 
-19.73 (-29.66 to -9.81) 
-26.97 (-43.95 to -10.01) 
2.21 (-44.46 to 48.88) 
0.79 
HbA1c at diagnosis (Ref <58 mmol/mol) 
58 to 80  
>80 mmol/mol 
238 115.22 (35.55 to 194.88) 
-92.60 (-179.71 to -5.48) 
-123.69 (-205.94 to -41.44) 
-58.44 (-140.34 to 23.45) 
41.91 (5.49 to 78.33) 
79.64 (58.46 to 100.82) 
44.28 (-0.63 to 89.19) 
-14.36 (-33.90 to -5.18) 
-31.51 (-42.77 to -20.25) 
0.01 
HbA1c at baseline (Ref <58 mmol/mol) 
58 to 80  
>80 mmol/mol 
334 63.40 (14.97 to 111.83) 
-43.81 (-97.59 to 9.98) 
-69.19 (-122.06 to -16.33) 
-0.87 (-50.59 to 48.86) 
46.41 (22.23 to 70.58) 
79.00 (57.10 to 100.91) 
12.03 (-14.24 to 38.30) 
-14.38 (-27.30 to -1.46) 
-33.40 (-45.10 to -21.71) 
0.001 
HbA1c tertiles at baseline (Ref Tertile 1) 
Tertile 2  
Tertile 3 
335 40.69 (13.26 to 68.12) 
-29.47 (-66.98 to 8.04) 
-53.64 (-90.67 to -16.61) 
23.82 (-4.47 to 52.12) 
58.15 (31.71 to 84.59) 
85.53 (59.86 to 111.21) 
-3.17 (-18.25 to 11.91) 
-21.98 (-36.12 to -7.84) 
-34.95 (-48.64 to -21.27) 
0.02 
BMI (WHO) z score at baseline (Ref 
normal weight) 
Overweight/obese 
309  
21.14 (-6.95 to 49.24) 
-18.15 (-53.90 to 17.60) 
 
48.10 (19.06 to 77.14) 
65.11 (42.29 to 87.94) 
 
-17.44 (-32.80 to -2.08) 
-23.87 (-36.05 to -11.68) 
0.74 
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Thin -2.26 (-46.01 to 41.48) 52.17 (17.51 to 86.83) -18.29 (-36.92 to 0.35) 
t=T1D duration; *Global Wald test (χ²); ref: reference group; WHO: World Health Organization. All models include √ and log*√ functions of time as both fixed and random effects 
 
 
